eHEALTH BureauCordLife, the Singapore-based stem cell bank, is exploring the possibility of starting a development unit in India to work on more applications for stem cells in the treatment of various diseases, including diabetes. CordLife collects, processes and stores umbilical cord and cord blood stem cells, which may later become potential source material for life saving treatments.CordLife currently has four research and development centres including in Holland, Singapore and Hong Kong working on improving the application of stem cells in the treatment of various ailments. In India, the company will partner an Indian hospital or those with necessary medical infrastructure to carry out the development work. The company plans to bring projects into India for which some research has already been done and that require development. Simon Hoo, General Manager

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.